NCT01849250View on ClinicalTrials.gov

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 11, 2016

Study Completion Date

April 22, 2020

Conditions

Benign Breast NeoplasmDuctal Breast Carcinoma In SituInvasive Breast CarcinomaLobular Breast Carcinoma In SituPaget Disease of the BreastStage IA Breast CancerStage IB Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer

Interventions

DRUG

Docosahexaenoic Acid

Given PO

OTHER

Placebo

Given PO

Trial Locations (4)

10032

Columbia University/Herbert Irving Cancer Center, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

77030

MD Anderson Cancer Center, Houston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT01849250 - Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors | Biotech Hunter | Biotech Hunter